retatrutide phase 2 results 2024 2025 Eli Lilly just announced striking 3 for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Lilly orforglipron oral GLP-1 phase

Sinclair discusses why some people may appear biologically younger or older than their chronological age

Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death

There is one study demonstrated a positive correlation between IFN- production and GLP-1R expression in patients with COPD

For procurement review, the practical question is whether the label, COA, catalog entry, and supplier documentation tell the same story

Diagnosis and management of ADHD in children

Sus beneficios mejor estudiados se relacionan con presin arterial y disfuncin erctil leve o moderada , pero no debe usarse como tratamiento ni reemplazar medicamentos